Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 37 for:    Acerta Pharma

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02362035
Recruitment Status : Active, not recruiting
First Posted : February 12, 2015
Last Update Posted : September 20, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021